Actively Recruiting

Age: 18Years +
All Genders
ID05939401

ANCABio - Study of Tumour Microenvironment and Biopsies to Predict Treatment Response and Outcome in Anal Cancer

Led by Sahlgrenska University Hospital · Updated on 2025-03-18

400

Participants Needed

2

Research Sites

104 weeks

Total Duration

On this page

Sponsors

S

Sahlgrenska University Hospital

Lead Sponsor

G

Göteborg University

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are investigating the tumor biology related to treatment response in patients with anal cancer. They aim to understand the tumor microenvironment, the location and interactions between tumor and immune cells, and the gene and protein expression in tumor and surrounding tissues. This study focuses on adult patients treated or diagnosed at Sahlgrenska University Hospital. Participants who are newly diagnosed or have a suspected recurrence will be invited to provide biopsies and blood samples during diagnostic exams performed under anesthesia. Additional biopsies may be collected during follow-up exams, surgery, or further anesthesia examinations after treatment. If biopsies cannot be taken before treatment, blood samples will still be collected. During the study, patients will undergo biopsies and blood sample collection at various time points including diagnosis, recurrence, and follow-up. Researchers will monitor the tumor microenvironment and circulating tumor DNA from 2024 to 2029. The study will gather detailed biological information to help predict treatment response and outcomes in anal cancer. Participation involves regular medical assessments and sample collections over several years.

CONDITIONS

Brief Title

A Study Regarding Tissue Response During and After Treatment for Anal Cancer

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Newly diagnosed or recurrent anal cancer
Not Eligible

You will not qualify if you...

  • No diagnosis of anal cancer
  • Contraindication to biopsies and blood samples

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

Diagnostic Evaluation

Duration - At diagnosis or suspected recurrence

Participants undergo diagnostic examinations including biopsies and blood samples under anaesthesia to assess their condition before treatment.

1 visit (in-person)

Long-term Monitoring

Duration - Up to 5 years

Participants have biopsies and blood samples taken during follow-up exams, surgery if scheduled, or examinations under anaesthesia after treatment ends to monitor tissue response and outcomes.

Periodic visits depending on treatment and follow-up schedule

Trial Site Locations

Total: 2 locations

1

Dept. of Surgery, Sahlgrenska University Hospital/Ostra

Gothenburg, Sweden, SE 416 85

Actively Recruiting

2

Sahlgrenska University Hospital

Gothenburg, Sweden

Actively Recruiting

Loading map...

Research Team

E

Eva Angenete PI, Professor

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Similar Trials

Anal Cancer and/or Precancer Screening: Performance Analysis...

Anal Intraepithelial Neoplasia 2

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here